Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type 2 diabetes.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly and Company (NYSE: LLY) is one of the best upside stocks to invest in now. On August 11, Eli Lilly announced its ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Trump administration demands lower U.S. prices on drugs like Mounjaro, forcing the pharmaceutical company to raise them in ...

Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Eli Lilly ( NYSE: LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 ...